Here's Jon Bon Jovi for Advil, Arnold Palmer for Xarelto and 48 more past and present celebrity endorsements of drugs, healthcare products and disease awareness campaigns.
Celebrity success or fail? Here's what the American Lung Association, Pfizer and Tim Daly likely did not see coming when they joined forces to raise awareness about pneumococcal pneumonia.
Heaven knows the industry is itself to blame for some of the dopier recurring imagery in its DTC spots, like models clad in white linen riding horses on deserted stretches of beach.
Tapping celebrities for brand or awareness campaigns ensures a high degree of attention, but such arrangements come with concerns that "regular" ones do not.
A pharma research forefather. An agency builder. A "guy you wanted in the room." These Medical Advertising Hall of Fame inductees are a professionally diverse and richly worthy trio.
It's possible that payers won't prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers' hands.
Prior to Medicines360's arrival on the scene, there were only three IUDs on the market. The lack of competition drove prices sky-high.
Sanofi is the category leader. Its product, Lantus Solostar, brought in $5.27 billion in US sales between October 2014 and September 2015.
New entrants in the type 2 diabetes treatment market share a similar goal: To solve patients' constant struggle with glycemic control.
Experts insist that R&D efforts in the category must mirror educational campaigns and lifestyle changes, and quickly.
Click the link below to access the Digital Edition of the January 2016 issue of MM&M, with all text, charts and pictures.
Ryan Olohan, National industry director, healthcare, Google
Halle Tecco, Managing director, Rock Health
Dr. Robert Wachter, Professor, chief of the division of hospital medicine, University of California, San Francisco
Ruchin Kansal, Executive director and head, business innovation, Boehringer Ingelheim
Aschkan Abdul Malek, CEO/co-founder, AlemHealth
Walter De Brouwer, Founder and CEO, Scanadu
Stephanie Bova, Senior director, Takeda Digital Accelerator, Takeda
Meg Columbia-Walsh, Global lead, digital healthcare, Cognizant
Entrepreneur in residence, Martin Trust Center for MIT
Michael Vinegar, director, medical e-strategy, Novartis
Sandra Elliott, VP, consumer technology and service development, Meridian Health
Dr. Somair Riaz, Founder, Skindroid
Dave Guiga, senior director, external partnerships & commercial innovations, AstraZeneca
T. J. Parker, CEO and co-founder, PillPack
Ronald Weidner, Founder and CEO, empower
Anish Sebastian, CEO and co-founder, BabyScripts
Chuck Gershman, Co-founder, president and COO, Kuveda
Nirinjan Yee, CEO and founder, BreathResearch
Sonny Vu, CEO, chairman, founder, Misfit
Judy Sewards, VP, digital strategy and data innovation, Pfizer
Naomi Fried, Former chief innovation officer, Boston Children's Hospital
Dr. Noah Craft, Co-founder and CEO, Science 37
Lucy Rose, President/owner, Lucy Rose & Associates
Fay Christodoulou, chief scientific officer, Miroculus
Jason Bornhorst, CEO/co-founder, Patient IO
Kevin Sayer, President and CEO, Dexcom
Greg Cohen, associate director of global strategic marketing, UCB
Risa Wexler, Senior director of media and US digital acceleration, Pfizer
Dr. Diego Miralles, Global head of innovation, Janssen
Bronwyn Spira, Founder and CEO, FORCE Therapeutics
Kurt Brenkus, Founder and CEO, Aver
Sander Flaum, Principal, Flaum Navigators
Markus Christen, Head of global development, Proteus Digital Health
Rob Royea, CEO and chairman, Cyrcadia Health
Amy Landucci, Global head of digital medicines, Novartis
Jörn Aldag, Former CEO, uniQure
Sara Colantonio, Project coordinator, Semeoticons
Ryan Beckland, Co-founder and CEO, Validic
Jane Sarasohn-Kahn, Founder, THINK-Health
Michelle Crouthamel, Project manager, GlaxoSmithKline
Here are the 40 executives, investors, entrepreneurs, designers and thinkers who are ushering the industry into its new technological golden era.
January marks the start of the 50th annual publication cycle of MM&M. We're also witnessing the industry enter its own technological golden era.
Dina Peck's Private View: It's a new year. Let's all commit to creating work in 2016 that inspires.
Apparently, Dr. Ezekiel Emanuel loves to open his window and shout "fire!"
Amazon's Echo—a voice-activated personal assistant like Siri—has been available to the public for a year now.
Layoffs at CPG companies have begun, including significant numbers in the research function at major corporations. Is healthcare market research insulated from this trend?
In a town where the main business is politics, the election of a new president heightens the intensity.
Social listening can help all along the value chain—from research and discovery to developing marketing plans and strategy.
How did the WWE keep me interested for the last 20 years?
With few exceptions, pharma brands haven't made much headway on Facebook. Marketers won't see real results until they cede control and stop chasing likes.
In the wake of an exposé on Amazon's corporate culture, pharma companies and agencies strive to keep employees as happy and satisfied as their clients.
With the huge advances in treatment comes a raft of concerns, among them daunting pricing pressures.
Wearables has been the buzziest of healthcare-related buzzwords. And yet here we are in January 2016, still awaiting their iPhone moment.
David Meek has been charged with building an oncology arm that matches the company's existing strengths in hematology and immunology.
Click the link below to access the Digital Edition of the December 2015 issue of MM&M, with all text, charts and pictures.
Anyone who thinks that the argument over off-label communications is just about marketing and sales is looking at the issue through very narrow blinders
Healthcare promotion: Happiness isn't the only emotion
Patient portals are clearly underutilized as a patient resource. Although their use is increasing among a population hungry for health information, what can industry do to foster and promote their use?
Big pharma has used multichannel marketing for years and medical-device makers have long utilized inside sales, but neither has systematically cracked the code on developing effective and fully integrated sales and marketing programs.
There is another revolution that is waiting to happen: one in how we get orphan drugs to patients who need them and help them stay on track with treatment.
It's no secret that speed matters in customer interface. Marc Iskowitz settles into the moderator's seat to find out how biopharma—an industry not known for moving with rapidity—is digitally shifting its commercial model into a higher gear
Content marketing continues to strike fear into the hearts of pharma marketers. Doing it properly requires courage, commitment, creativity—and perhaps a little wiggle room to fail and learn. James Chase looks at three flagship OTC content programs that might lend a bit of inspiration to the Rx world
Healthcare may seem to have been unscarred by the ongoing rash of high-profile cyber-attacks, at least compared with retail and financial organizations. But to hear security pros tell it, the industry is increasingly finding itself as much of a target as companies in other sectors—if not more of one. Karen Epper Hoffman surveys the potential damage
The year 2015 may have lacked a hall-of-fame debut on par with 2014's hep.-C launches, but the year featured its share of intrigue in the form of sky-high valuations forcing big organizations to adjust their M&A approach and more. In this Q&A, Jon Gardner, deputy news editor at EvaluatePharma's EP Vantage, reads the tea leaves and hands out some awards—including Company of the Year honors for a controversial candidate
A peek at 159 aspiring agents, with profiles on 17 that could shoot to stardom. Rebecca Mayer Knutsen has the forecast
To hear politicians tell it—especially the ones seeking President Obama's job—pharma is motivated by profit and needs to be brought to heel. The reality of the situation, inside DC and out, is just a tad more complex. Larry Dobrow takes a closer look at what might be coming down the policy pipeline Illustration by Alex Fine
"Partnering up in complete transparency is the best possible scenario for patients"
Hackathons are a dime a dozen in healthcare. But are they encouraging the community to collaborate on solving the most nettlesome problems, or merely to tinker on me-too solutions?
Click the link below to access the Digital Edition of the November 2015 issue of MM&M, with all text, charts and pictures.
Pharma marketers of all stripes came together on October 1 in New York City to celebrate another outstanding year's worth of work—and play Photos: Dan D'Errico
Would you expect that patient power exerted through social media might shake the job of a high-level FDA center director?
That 700% price hike created an issue that threatens years of pharma progress
The neurology space is gearing up to shake free of its decade-long stagnancy, with sector leaders and runners-up alike angling to push the boundaries. What that means: Imminent advances in genetic sequencing, targeted treatments and diagnostics, all designed to get to the biological root of neurological disorders. Rebecca Mayer Knutsen explains
It's an entirely different day for patient advocacy, yet we've only scratched the surface. Advocates and their pharma counterparts discuss what's standing in the way of deeper collaboration. Marc Iskowitz chairs a lively debate
To date, pharma marketers have viewed interactive video as more or less a curio—a tactic best assigned to next year's to-do list. But in doing so, they're missing a huge opportunity to connect in ways that more linear forms of advertising can't match. By way of IKEA and Coldplay, Mitch Apley explains
As pharma marketers continue on their age-old quest to engage physicians, the either/or choice between reps and digital tactics has largely gone away in favor of programs that incorporate both. At the same time, certain segments of the business are still finding their way in the brave new digital world. Larry Dobrow surveys the scene
Programmatic buying has started to take over the placement of digital ads, to the tune of $15 billion in 2015 sales. Is pharma in the process of following suit or will concerns about privacy and fraud dampen industry enthusiasm? Barbara Peck assesses the pros and cons
"Gene therapy is a collection of small details. It's not a secret sauce."
Choosing the best of the best is never easy. It is a challenging task. Our panel of more than 100 of the industry's top thinkers, opinion makers and creatives used their vast expertise and tried-and-true insight to score the hundreds of entries for the MM&M Awards 2015. Please see the attached pdf (below) to see this year's roster.
Welcome to this special showcase of the winning work from the MM&M Awards 2015
Recognizes an exemplary campaign or marketing initiative that distinguishes itself as "best in show."
Recognizes exceptional contribution to healthcare by an individual, a team, an organization, association or other relevant group.